Instrumento de mejora del agua, el saneamiento y la higiene en los establecimientos de
salud “WASH FIT": guía práctica para mejorar la calidad de la atención mediante los …

Shorter (6–9 months), fully oral regimens containing new and repurposed drugs are now the
first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long …

Highlights•“Old” molecules and targets represent attractive start points.•Modern medicinal
chemistry is essential to convert a compound hit into a drug.•Nutritional flexibility makes …

Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-
drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially …

世界卫生组织(World Health Organization, WHO) 发布了新的《 全球结核病报告2022》(以下
简称报告), 报告指出新型冠状病毒感染加重了结核病的负担, 严重影响了全球结核病控制的进程 …

Operational handbook on tuberculosis. Module 4: Treatment of drug-resistant tuberculosis
treatment, is a derivative product arising from the guideline on the same topic. This …

Background Effectiveness, safety, tolerability, and adherence are critical considerations in
shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include …

Recent advances in the treatment of tuberculosis (TB) have led to improvements
unprecedented in our lifetime. Decades of research in developing new drugs, especially for …

BACKGROUND: Evidence of the effectiveness of the WHO-recommended design of longer
individualized regimens for multidrug-or rifampicin-resistant TB (MDR/RR-TB) is limited …

Background There are scarce data on the clinical outcomes of persons retreated with
new/companion anti-tuberculosis (TB) drugs for multidrug-and rifampicin-resistant …